We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Paroxetine/Bupropion in Suicide Attempters/Ideators With Major Depression

This study has been terminated.
(Interim analysis showed differential treatment effects.)
Sponsor:
ClinicalTrials.gov Identifier:
NCT00429169
First Posted: January 31, 2007
Last Update Posted: November 21, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
National Institute of Mental Health (NIMH)
Information provided by (Responsible Party):
New York State Psychiatric Institute
Results First Submitted: December 11, 2012  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Condition: Depression
Interventions: Drug: Paroxetine
Drug: Bupropion

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Recruitment dates were 2/2005-7/2009 with follow-up completed in January 2010.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
N=101 subjects enrolled, but N=23 did not return after enrollment, so N=78 were randomized.

Reporting Groups
  Description
Paroxetine Participants will receive paroxetine for 8 weeks
Bupropion Participants will receive bupropion for 8 weeks

Participant Flow:   Overall Study
    Paroxetine   Bupropion
STARTED   38   40 
COMPLETED   36 [1]   38 [2] 
NOT COMPLETED   2   2 
Lost to Follow-up                0                1 
Ineligibility discovered after entry                2                1 
[1] 2 subjects excluded due to re-diagnosis/ineligibility.
[2] 2 subjects excluded: re-diagnosis/ineligibility (1), and did not return after randomization (1).



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Paroxetine Participants will receive paroxetine for 8 weeks
Bupropion Participants will receive bupropion for 8 weeks
Total Total of all reporting groups

Baseline Measures
   Paroxetine   Bupropion   Total 
Overall Participants Analyzed 
[Units: Participants]
 36   38   74 
Age 
[Units: Participants]
Count of Participants
     
<=18 years      0   0.0%      0   0.0%      0   0.0% 
Between 18 and 65 years      36 100.0%      38 100.0%      74 100.0% 
>=65 years      0   0.0%      0   0.0%      0   0.0% 
Age 
[Units: Years]
Mean (Standard Deviation)
 35.2  (12.8)   37.9  (11.9)   36.4  (12.7) 
Sex: Female, Male 
[Units: Participants]
Count of Participants
     
Female      21  58.3%      21  55.3%      42  56.8% 
Male      15  41.7%      17  44.7%      32  43.2% 
Region of Enrollment 
[Units: Participants]
     
United States   36   38   74 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Go-No go Test   [ Time Frame: Measured at Baseline and Week 8 ]

2.  Primary:   Scale for Suicidal Ideation   [ Time Frame: Baseline and Week 8 ]

3.  Primary:   Occurrence of Suicidal Ideation or Acts Necessitating a Change in Treatment   [ Time Frame: Measured at Month 6 ]

4.  Secondary:   Brain Activity Measured by BOLD Signal With fMRI During a Reward Processing Task.   [ Time Frame: Baseline and Week 8. ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.  


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
  1. Significant dropout meant the number of subjects with analyzable data was smaller than the number enrolled.
  2. An interim analysis of this pilot study showed differential treatment effects so a decision was made to stop enrollment early.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Michael F. Grunebaum, MD
Organization: Columbia University/NYSPI
phone: 212-543-5842
e-mail: mfg14@columbia.edu


Publications of Results:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: New York State Psychiatric Institute
ClinicalTrials.gov Identifier: NCT00429169     History of Changes
Other Study ID Numbers: #5933R
K23MH076049 ( U.S. NIH Grant/Contract )
DSIR 8KRT-AT
First Submitted: January 29, 2007
First Posted: January 31, 2007
Results First Submitted: December 11, 2012
Results First Posted: January 24, 2013
Last Update Posted: November 21, 2017